Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2

NCT04420611 is registered in ClinicalTrials.gov with Youssef Daali as lead sponsor.

NCT NCT04420611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04420611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2
Lead sponsor
Youssef Daali
Phase
Observational
Overall status
Completed
Start date
October 1, 2020
Completion date
December 30, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy